Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Sociodemographic and Clinical Characteristics of Patients with Atopic Dermatitis in Colombia:Preliminary Results of Rendac

Speaker(s)

Alvis Zakzuk N1, Fierro-Lozada JD2, Sanchez Zapata MJ2, Victoria Chaparro AM3, Cera - Coll CV2, Moyano L1, Castillo-Molina D2, Covo-Camacho SA4, Alvis Guzman N5
1ALZAK Foundation, Grupo de Investigación ALZAK, Cartagena, BOL, Colombia, 2Fundación para la Investigación en Dermatología - FUNINDERMA, Bogota, CUN, Colombia, 3Centro Médico Farallones, Cali, Colombia, 4Universidad del Rosario, Bogotá, Colombia, 5ALZAK Foundation- Universidad De La Costa, Barranquilla, Colombia

Presentation Documents

OBJECTIVES: We aim to describe the sociodemographic and clinical characteristics and treatment patterns of patients with Atopic Dermatitis (AD) in Colombia, due to the lack of epidemiological information about this dermatitis in our country

METHODS: An observational, descriptive, and cross-sectional study was carried out. The data used was from the first phase of the National Registry of Patients with Atopic Dermatitis in Colombia (RENDAC, for its acronym in Spanish). This data was collected between July and September 2021. Absolute and relative frequencies were estimated. In addition, we estimated contingency tables using the SCORAD variable, which shows the level of severity of the AD.

RESULTS: A total of 644 patients were analyzed, 345 were women (53.6%) and 390 were under 18 years (60.6%). Respecting social variables, we found that 81.5% live in urban areas (n=524), and 60.9% (n=392) have health care access through a privacy health insurance company. In 235 patients (36.5%) was found other skin comorbidities. The 27,5% of patients (n=177) had severe AD and are treated mainly with high potency topical corticoid and systemic treatment.

CONCLUSIONS: After one-year, RENDAC show mainly patients of young age, female, belonging to urban areas and being affiliated to a privacy health insurance company. It is necessary to enlarge this sample to really understand the epidemiological behavior of AD in Colombia.

Code

EPH23

Topic

Clinical Outcomes, Economic Evaluation, Epidemiology & Public Health

Topic Subcategory

Clinician Reported Outcomes, Public Health, Value of Information

Disease

Biologics and Biosimilars, Drugs, Pediatrics